Category: Guest content

Estimated costs of production and potential prices for the WHO Essential Medicines List

This article was originally published by Andrew M Hill, Melissa J Barber, and Dzintars Gotham in BMJ Global Health Jan 2018, 3 (1) e000571 under a Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license. Abstract Introduction There are persi…


Decision-making in product portfolios of pharmaceutical research and development – managing streams of innovation in highly regulated markets

This article was originally published by Antti Jekunen in Drug Des Devel Ther. 2014; 8: 2009–2016 under a Creative Commons Attribution – Non Commercial (unported, v3.0) License. Abstract Decision-making is a core function…
The post Decision-makin…


Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics

Originally published by  J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski in Front. Oncol., 14 November 2017. Abstract The repositioning or…
The post Giving Drugs a Second…


Biotech in Countries Starting with “I” – Part 12: Israel

This is a guest post from Susan K Finston, President of Finston Consulting.  A little over five years ago I penned the first installment in this irregular series, focused on Israel’s tech transfer prowess and efforts to encourage innovative life-sciences. I tracked the Start-Up Nation’s incremental progress here.    In a nutshell, Israel leveraged excellence in basic science and […]


Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending

Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License. Abstract Policy Points: Our study indicates that there are opportunities…
The post Comparing Generic Dru…


Contribution of NIH funding to new drug approvals 2010–2016

This article was originally published by Ekaterina Galkina Cleary, Jennifer M. Beierlein, Navleen Surjit Khanuja, Laura M. McNamee and Fred D. Ledley in PNAS under a Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC…
The po…


Tracking 20 Years of Compound-to-Target Output from Literature and Patents

This article was originally published by Christopher Southan, Peter Varkonyi, Kiran Boppana, Sarma A.R.P. Jagarlapudi, and Sorel Muresan at PLoS ONE 8(10): e77142. Abstract The statistics of drug development output and…
The post Tracking 20 Years…


Celgene vs. Dr. Reddy’s Revlimid patent infringement case depends on polymorph stability; lack thereof may favor Celgene position – experts

This article was originally published on November 30th 2017 by Hamish McDougall and Alaric DeArment of BioPharm Insight, part of GlobalData. Polymorph differences support noninfringement argument Trace solvate amount could destabalise…
The post C…


Making Medicines Affordable: A National Imperative

Consumer access to effective and affordable medicines is an imperative for public health, social equity, and economic development, but this need is not being served adequately by the biopharmaceutical sector,…
The post Making Medicines Affordable…


Patent Protection Strategies

This article was originally published by Himanshu Gupta, Suresh Kumar, Saroj Kumar Roy, and R. S. Gaud at J Pharm Bioallied Sci. 2010 Jan-Mar; 2(1): 2–7. Abstract It is widely recognized…
The post Patent Protection Strategies appeared first on Dr…


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: